Ipsen S.A. (IPN) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 322 PAGES: 46

More Info
									                Ipsen S.A. (IPN) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH15876FSA                                                                                           Publication Date: JAN 2013

          65, quai Georges Gorse                             Phone              +33 1 58335000                  Revenue          1,234.91 (million EUR)
          Boulogne-Billancourt, Ile-de-France                Fax                +33 1 58335001                  Net Profit       0.42 (million EUR)
          92100                                              Website            www.ipsen.com                   Employees        4,500
                                                                                                                                 Pharmaceuticals           &
          France                                             Exchange           IPN [Euronext Paris]            Industry
                                                                                                                                 Healthcare

       Company Overview
       Ipsen S.A. (Ipsen) is a global specialty pharmaceutical company. It develops and markets drugs and therapeutic products. It
       provides specialty care drugs in uro-oncology, endocrinology, neurology and hematology. In primary care, the company produces
       therapeutic products for the treatment of gastroenterological and neurological diseases. The company markets its products in
       over 100 countries in Europe, North America and Asia. Ipsen is headquartered in Paris, France.


       Ipsen intends to grow, specifically in the neurology and endocrinology therapeutics areas, and provide innovative specialty
       medicines to the US patients.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Ipsen S.A., SWOT Analysis
         Marc de Garidel                     Chairman                                 Strengths                              Weaknesses
         Anne Beaufour                       Director
                                                                                      Diversified Product Offerings          Limited Liquidity
         Henri Beaufour                      Director
                                                                                      Global Presence                        Increasing Operating Expenses
         Christophe Verot                    Director
         Antoine Flochel                     Vice-Chairman
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Strategic Agreements                   Stringent Government
       Share Data                                                                                                            Regulations
                                                                                      Strong Product Pipeline
         Ipsen S.A.
                                                                                                                             Growing Parallel Trade
        Share Price (EUR) as on 15-Jan-                                24.70
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (EUR)                                                         0.0        GlobalData
        Market Cap (million EUR)                                       2,054
        Enterprise Value (million EUR)                                 1,997
        Shares Outstanding (million)                                       83
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Oct 31, 2012         Inspiration Biopharma Seeks            Chapter 11
                                                                                                           Bankruptcy Protection
                                                                                      Oct 29, 2012         Ipsen Reports Revenue Of €294.9m In Q3
                                                                                                           2012
                                                                                      Aug 28, 2012         Ipsen Reports Revenue Of €675m In H1 2012
                                                                                      Aug 28, 2012         Ipsen To Eliminate 100 Jobs
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData



       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Ipsen S.A. (IPN) - Financial and Strategic SWOT Analysis Review                                                                Reference Code: GDPH15876FSA
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Ipsen S.A. - Key Facts ........................................................................................................................................................................ 5
       Ipsen S.A. - Key Employees ............................................................................................................................................................... 6
       Ipsen S.A. - Key Employee Biographies ............................................................................................................................................. 7
       Ipsen S.A. - Major Products and Services .......................................................................................................................................... 8
       Ipsen S.A. - Pharmaceutical Pipeline Products Data........................................................................................................................ 10
          Ipsen S.A., Pipeline Products by Therapy Area ............................................................................................................................ 10
          Ipsen S.A., Pipeline Products by Development Phase ................................................................................................................. 11
       Ipsen S.A. - History .......................................................................................................................................................................... 13
       Ipsen S.A. - Company Statement ..................................................................................................................................................... 18
       Ipsen S.A. - Locations And Subsidiaries .......................................................................................................................................... 19
          Head Office ................................................................................................................................................................................... 19
          Other Locations & Subsidiaries ..................................................................................................................................................... 19
       Section 2 – Company Analysis ......................................................................................................................................................... 21
       Ipsen S.A. - Business Description .................................................................................................................................................... 21
       Ipsen S.A. - SWOT Analysis............................................................................................................................................................. 22
          SWOT Analysis - Overview........................................................................................................................................................... 22
          Ipsen S.A. - Strengths ................................................................................................................................................................... 22
             Strength - Diversified Product Offerings .................................................................................................................................... 22
             Strength - Global Presence ....................................................................................................................................................... 22
             Strength - Sturdy Research and Development Activities ........................................................................................................... 22
          Ipsen S.A. - Weaknesses.............................................................................................................................................................. 22
             Weakness - Limited Liquidity..................................................................................................................................................... 22
             Weakness - Increasing Operating Expenses ............................................................................................................................ 23
          Ipsen S.A. - Opportunities ............................................................................................................................................................. 23
             Opportunity - Strategic Agreements .......................................................................................................................................... 23
             Opportunity - Strong Product Pipeline ....................................................................................................................................... 23
             Opportunity - Growth Prospects: Emerging Markets ................................................................................................................. 23
          Ipsen S.A. - Threats ...................................................................................................................................................................... 24
             Threat - Stringent Government Regulations .............................................................................................................................. 24
             Threat - Growing Parallel Trade ................................................................................................................................................ 24
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 24
       Ipsen S.A. - Key Competitors ........................................................................................................................................................... 25
       Section 3 – Company Financial Ratios ............................................................................................................................................. 26
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 26
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 26
       Performance Chart ........................................................................................................................................................................... 28
       Financial Performance...................................................................................................................................................................... 28
       Financial Ratios - Interim Ratios....................................................................................................................................................... 29
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 30
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 31
          Ipsen S.A., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ........................................................................... 31



Ipsen S.A. (IPN) - Financial and Strategic SWOT Analysis Review                                                                                                Reference Code: GDPH15876FSA
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Ipsen S.A., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ........................................................................... 32
          Ipsen S.A., Medical Equipment, Deals By Year, 2007 to YTD 2013 ............................................................................................. 33
          Ipsen S.A., Medical Equipment, Deals By Type, 2007 to YTD 2013............................................................................................. 34
       Ipsen S.A., Recent Deals Summary ................................................................................................................................................. 35
       Section 5 – Company’s Recent Developments ................................................................................................................................ 36
          Ipsen S.A., Recent Developments ................................................................................................................................................ 36
             Oct 31, 2012: Inspiration Biopharma Seeks Chapter 11 Bankruptcy Protection ....................................................................... 36
             Oct 29, 2012: Ipsen Reports Revenue Of €294.9m In Q3 2012 ................................................................................................ 36
             Aug 28, 2012: Ipsen Reports Revenue Of €675m In H1 2012 .................................................................................................. 38
             Aug 28, 2012: Ipsen To Eliminate 100 Jobs .............................................................................................................................. 39
             Jul 11, 2012: Ipsen Decides To Retain Dreux-Based Primary Care Industrial Facility Within Group’s Scope........................... 39
             Jun 13, 2012: Kymos Pharma launches R&D Division In Biotechnology At Barcelona Science Parks ..................................... 40
								
To top